Genmab A/S (GMAB) trades at a trailing P/E of 4.4, forward P/E of 24.1. Trailing earnings yield is 22.51%, forward earnings yield 4.15%. PEG 1.09. Graham Number is $366.56.
Criteria proven by this page:
Overall SharesGrow Score: 76/100 with 5/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 59.1 | 1.16 | 14.54 | 38.63 | - |
| 2017 | 58.6 | -6.83 | 10.32 | 27.36 | - |
| 2018 | 44.7 | 1.37 | 8.20 | 21.73 | - |
| 2019 | 43.3 | 1.00 | 6.67 | 17.46 | - |
| 2020 | 33.9 | 0.30 | 8.44 | 15.96 | - |
| 2021 | 57.2 | -1.50 | 7.62 | 20.09 | - |
| 2022 | 35.3 | 0.42 | 7.05 | 13.27 | - |
| 2023 | 32.6 | -1.56 | 4.48 | 8.60 | - |
| 2024 | 12.4 | 0.15 | 2.65 | 4.51 | - |
| 2025 | 19.9 | -0.23 | 3.28 | 5.14 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $1.92 | $1.82B | $1.19B | 65.4% |
| 2017 | $1.78 | $2.37B | $1.1B | 46.7% |
| 2018 | $2.37 | $3.03B | $1.47B | 48.7% |
| 2019 | $3.40 | $5.37B | $2.17B | 40.4% |
| 2020 | $7.22 | $10.11B | $4.76B | 47.1% |
| 2021 | $4.48 | $8.48B | $2.96B | 34.9% |
| 2022 | $8.26 | $14.6B | $5.45B | 37.4% |
| 2023 | $6.60 | $16.47B | $4.35B | 26.4% |
| 2024 | $12.14 | $21.53B | $7.84B | 36.4% |
| 2025 | $1.54 | $3.72B | $963.76M | 25.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $1.23 | $0.87 – $1.84 | $4.32B | $4.27B – $4.36B | 8 |
| 2027 | $1.80 | $1.08 – $2.35 | $5.1B | $4.62B – $5.42B | 7 |
| 2028 | $2.59 | $1.79 – $3.36 | $6.14B | $6.09B – $6.18B | 9 |
| 2029 | $2.42 | $2.22 – $2.59 | $6.18B | $5.78B – $6.52B | 3 |
| 2030 | $2.68 | $2.46 – $2.87 | $6.51B | $6.1B – $6.87B | 3 |
